Lars Bardtrum
Soborg, Denmark
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 20 publications
Semaglutide Treatment in Young Adults Living With Type 2 Diabetes: A Post Hoc Analysis From the SUSTAIN and PIONEER Clinical Trials.
Journal: Diabetes, obesity & metabolism
Published: January 16, 2026
Baseline characteristics from evoke and evoke+: Two phase 3 randomized placebo-controlled trials of semaglutide in participants with early-stage symptomatic Alzheimer's disease.
Journal: Alzheimer's & dementia (New York, N. Y.)
Published: September 05, 2025
An effort to enhance the clinical translatability of caprate-based tablet formulations in gastric peptide delivery.
Journal: Drug delivery and translational research
Published: July 28, 2025
Determinants of Liraglutide Treatment Discontinuation in Type 1 Diabetes: A Post Hoc Analysis of ADJUNCT ONE and ADJUNCT TWO Randomized Placebo-Controlled Clinical Studies.
Journal: Journal of diabetes science and technology
Published: December 24, 2024
Combining SNAC and C10 in oral tablet formulations for gastric peptide delivery: A preclinical and clinical study.
Journal: Journal of controlled release : official journal of the Controlled Release Society
Published: April 15, 2024
Efficacy and safety of once-daily oral semaglutide 25 mg and 50 mg compared with 14 mg in adults with type 2 diabetes (PIONEER PLUS): a multicentre, randomised, phase 3b trial.
Journal: Lancet (London, England)
Published: May 15, 2023
Greater Combined Reductions of HbA1c ≥ 1.0% and Body Weight Loss ≥ 5.0% or ≥ 10.0% with Orally Administered Semaglutide Versus Comparators.
Journal: Diabetes therapy : research, treatment and education of diabetes and related disorders
Published: January 27, 2023
Body weight loss with oral semaglutide is mediated predominantly by effects other than gastrointestinal adverse events in patients with type 2 diabetes: A post hoc analysis.
Journal: Diabetes, obesity & metabolism
Published: September 14, 2022
Efficacy and safety of liraglutide in type 1 diabetes by baseline characteristics in the ADJUNCT ONE and ADJUNCT TWO randomized controlled trials.
Journal: Diabetes, obesity & metabolism
Published: May 27, 2021
Commentary to "Differential Effect of Hypoalbuminemia on Hypoglycemia on Type 2 Diabetes Patients Treated with Insulin Glargine 300 U/ml and Insulin Degludec" by Kawaguchi et al. Diabetes Therapy 2019.
Journal: Diabetes therapy : research, treatment and education of diabetes and related disorders
Published: November 18, 2019
A greater proportion of participants with type 2 diabetes achieve treatment targets with insulin degludec/liraglutide versus insulin glargine 100 units/mL at 26 weeks: DUAL VIII, a randomized trial designed to resemble clinical practice.
Journal: Diabetes, obesity & metabolism
Published: September 25, 2019
IDegLira Improves Glycemic Control in Japanese Patients with Uncontrolled Type 2 Diabetes on Premixed Insulin Therapy.
Journal: Diabetes therapy : research, treatment and education of diabetes and related disorders
Published: September 12, 2019
Last Updated: 09/26/2026